Skip to main content

Table 3 Patient characteristics associated with statin and ACEI/ARB prescribing at in-person office visits at 10 community health centers in Oregon where the medication(s) was/were clinically indicateda, June 2011 to May 2014

From: Cardiovascular care guideline implementation in community health centers in Oregon: a mixed-methods analysis of real-world barriers and challenges

  Office visitsb where a statin indicated Office visitsb where an ACEI/ARB was indicated
Number of encountersc % with an statin Rx < = 2 days p-value Number of encountersc % with an ACEI/ARBs Rx < = 2 days p-value
Total 11588 (13.2)   9887 (15.8)  
Patient characteristics
 Sex    <.0001    <.0001
  Male 4198 (15.7)   3819 (17.9)  
  Female 7390 (11.8)   6068 (14.5)  
 Age    <.0001    0.0607
  18–39 1582 (12.2)   747 (17.9)  
  40–54 3060 (15.5)   2473 (16.7)  
  55–75 6946 (12.5)   6667 (15.3)  
 Race/ethnicity    <.0001    <.0001
  Hispanic 3721 (17.7)   2714 (22.2)  
  Non-Hispanic White 5460 (10.8)   5035 (12.5)  
  Non-Hispanic Other 2298 (11.7)   2032 (15.4)  
  Missing/Unknown 109 (13.8)   106 (20.8)  
 Language    <.0001    <.0001
  English 6918 (10.7)   6016 (13.0)  
  Spanish 3303 (18.3)   2401 (23.1)  
  Other 1321 (13.6)   1435 (15.4)  
  Missing/Unknown 46 (10.9)   35 (20.0)  
 % of Federal Poverty Level at encounter    0.0293    0.2398
   < 100% 8568 (12.9)   7294 (15.5)  
  100–199% 2177 (13.1)   1888 (16.3)  
   > = 200% 751 (16.8)   639 (17.8)  
  Missing/Unknown 92 (12.0)   66 (21.2)  
 Insurance at encounter    <.0001    <.0001
  Uninsured 3817 (18.2)   2542 (26.1)  
  Insured 7759 (10.8)   7330 (12.3)  
  Missing/Unknown 12 -   15 -  
 Patient smoking status    0.042    <.0001
  Not current smoker 8917 (13.6)   7448 (16.7)  
  Current smoker 2631 (11.8)   2403 (12.6)  
  Missing/Unknown 40 (17.5)   36 (47.2)  
 Patient has active diagnosis of CVD    0.0015    <.0001
  No CVD 9984 (13.6)   7813 (17.6)  
  Has CVD 1604 (10.7)   2074 (9.2)  
 Patient has active diagnosis of HTN    0.1494    0.3498
  No HTN 5316 (13.7)   4026 (15.4)  
  Has HTN 6272 (12.8)   5861 (16.1)  
 Patient has active diagnosis of liver disease    <.0001    <.0001
  No liver disease 9946 (13.9)   8572 (16.5)  
  Has liver disease 1642 (9.1)   1315 (11.3)  
 Patient has active diagnosis of kidney disease    <.0001    <.0001
  No kidney disease 10759 (13.6)   8614 (17.3)  
  Has kidney disease 829 (8.1)   1273 (6.3)  
 BMI    0.2842    0.0009
   < 25 1266 (13.8)   1333 (12.5)  
   > = 25 9914 (13.2)   8251 (16.3)  
  Missing/Unknown 408 (10.8)   303 (18.8)  
 BP control    0.1188    <.0001
   < 120/80 3174 (12.4)   2834 (9.4)  
  120/80 to 139/89 6375 (13.1)   5291 (15.2)  
  140/90 to 159/99 1702 (14.7)   1459 (26.6)  
   > = 160/100 334 (15.3)   301 (35.5)  
  Missing/Unknown 3 (33.3)   2 -  
 HbA1c control    <.0001    <.0001
   < 7 5115 (10.3)   4398 (12.8)  
   > = 7 6197 (15.7)   5192 (18.4)  
  Missing/Unknown 276 (11.6)   297 (16.5)  
 LDL control    <.0001    <.0001
   < =100 or missing 4744 (9.6)   5867 (14.3)  
  100 to 129 4163 (13.7)   2194 (18.0)  
  > = 130 2681 (18.9)   1826 (18.1)  
  1. Abbreviations: ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blockers, BMI Body Mass Index; BP blood pressure, CVD cardiovascular disease, HbA1c glycated hemoglobin, HTN hypertension, LDL-low-density lipoproteins, Rx prescription
  2. aPoint-of-care alert for specified drug class fired at the visit
  3. bOffice visits defined as in-person encounters at a study clinic where the provider was a MD, PA, NP, or resident, and the encounter Evaluation & Management CPT code was in: 99201-99205; 99212-99215; 99243; 99385-99387; 99395-99397
  4. cVisit counts are not mutually exclusive, e.g., if both types of BPA fired at a visit, the visit is counted in both the statin and ACEI/ARB columns. p-value from chi square test for independence between characteristic and outcome of Rx < = 2 days